Investigational drug · Phase 3
STSP-0601
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hemophilia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "STSP-0601"
First trial start
2025
Mar 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STSP-0601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "STSP-0601" as an intervention, largest first.
- A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With InhibitorCompleted
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05027230 · 77 participants · Start Oct 12, 2021 · Primary completion Jul 15, 2023
Drug: STSP-0601 for Injection; STSP-0601 for Injection · For: Hemophilia
Sites: Tianjin, China
- Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia PatientsPivotal-lookingActive, not recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.Industry
NCT06922045 · 40 participants · Start Mar 26, 2025 · Primary completion Sep 2026
Drug: STSP-0601 for Injection · For: Hemophilia
Sites: Hefei, China; Lanzhou, China; Guangzhou, China · 18 sites in all
- Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without InhibitorCompleted
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05619926 · 32 participants · Start Jan 9, 2023 · Primary completion Aug 25, 2023
Drug: STSP-0601 for Injection · For: Hemophilia
Sites: Chongqing, China; Lanzhou, China; Shenzhen, China · 12 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06289166 · 25 participants · Start Mar 18, 2024 · Primary completion Oct 17, 2024
Drug: STSP-0601 for Injection · For: Hemophilia
Sites: Hefei, China; Chongqing, China; Fuzhou, China · 20 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT04747964 · 16 participants · Start Jan 15, 2020 · Primary completion Apr 19, 2021
Drug: STSP-0601 for Injection; STSP-0601 for Injection and 4 more · For: Hemophilia
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Innovations in Haemostasis Management in China: From Gene Therapy to Novel Rebalancing Strategies.
Liu W, Xiao X, Xu J, et al. · Haemophilia 2026
- Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.
Liu W, Xue F, Fu R, et al. · J Thromb Haemost 2023
Also in development for Hemophilia
- bypassing agentsClotting factor concentrates, CFCPhase 33 trials
Sanofi · Hemophilia, Von Willebrand Disease, Type 3
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.